Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H26N4O5S |
Molecular Weight | 434.509 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC1=CC=C(CSCCNC(NCC2=CC=C3OCOC3=C2)=C[N+]([O-])=O)O1
InChI
InChIKey=HXRSXEDVVARPHP-UDWIEESQSA-N
InChI=1S/C20H26N4O5S/c1-23(2)11-16-4-5-17(29-16)13-30-8-7-21-20(12-24(25)26)22-10-15-3-6-18-19(9-15)28-14-27-18/h3-6,9,12,21-22H,7-8,10-11,13-14H2,1-2H3/b20-12+
Niperotidine is an H2 antagonist structurally related to ranitidine. H2 antagonists inhibit gastric acid secretion by selectively blocking histamine receptor type 2. Niperotidine was proposed for the treatment of peptic ulcer. Bedtime dose of niperotidine inhibits nocturnal gastric acid secretion in healthy subjects. The duration of niperotidine action was 5 to 7 hours. Twenty-five cases of acute hepatitis (including one death from fulminant hepatitis) associated with niperotidine use were reported in Italy between March and August 1995 and drug was withdrawn from the market. The methylenedioxy group of niperotidine is known to undergo metabolism to catechol and quinone metabolites.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9314138
Daily dose: 230 - 460 mg
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA05
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
||
|
WHO-VATC |
QA02BA05
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID20101674
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
284-304-0
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
5857
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
SUB09301MIG
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
DB13760
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
100000083906
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
12JBD7U72K
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
C073716
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
C90863
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
66753191
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
NIPEROTIDINE
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
4002
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
CHEMBL1909284
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY | |||
|
84845-75-0
Created by
admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)